Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 366

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 366
---
 independent registered public accounting firm and management;

    ●
    reviewing and providing
    oversight of any related person transactions, including establishing such policies and procedures as appropriate to facilitate such
    review; and

    ●
    preparing the audit committee
    report required by the SEC rules (which is included on page 11 of this proxy statement).

The
Audit Committee charter is available on the Investors page of our website at www.indaptusrx.com. The members of the Audit Committee
are Mr. Hayes, Ms. Karah, and Dr. Martell. Mr. Hayes serves as the Chairperson of the committee. Our Board has affirmatively determined
that each of Mr. Hayes, Ms. Karah, and Dr. Martell is independent for purposes of serving on an audit committee under Rule 10A-3 promulgated
under the Exchange Act and the Nasdaq Rules, including those related to Audit Committee membership.

The
members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules. In addition, our Board
of Directors has determined that Mr. Hayes qualifies as an “audit committee financial expert,” as such term is defined in
Item 407(d)(5) of Regulation S-K, and under the similar Nasdaq Rules requirement that the Audit Committee have a financially sophisticated
member.

78

Compensation
Committee

Our
Compensation Committee is responsible for assisting the Board in the discharge of its oversight responsibilities relating to the evaluation
of our executive officers (including the Chief Executive Officer), determining the compensation of our executive officers, and overseeing
the management of risks associated therewith. In fulfilling its purpose, our Compensation Committee has the following principal duties:

    ●
    reviewing and
    approving, or recommending for approval by the Board, our overall compensation strategy and policies, including evaluating risks
    associated with our compensation policies and practices;

    ●
    reviewing and approving,
    or recommending for approval by the Board, the compensation of our CEO and our other executive officers;

    ●
    overseeing and administering
    our cash and equity incentive plans;

    ●
    reviewing and making recommendations
    to the Board of Directors with respect to non-employee director compensation;

    ●
    reviewing and discussing
    annually with management our “Compensation Discussion and Analysis,” to the extent required; and

    ●
    preparing the annual compensation
    committee report, to the extent required by SEC rules.

The